{"id":542775,"date":"2021-05-11T18:48:01","date_gmt":"2021-05-11T18:48:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=542775"},"modified":"2021-05-11T18:48:01","modified_gmt":"2021-05-11T18:48:01","slug":"car-tcell-therapy-for-multiple-myeloma-market-analysis-market-size-trends-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/car-tcell-therapy-for-multiple-myeloma-market-analysis-market-size-trends-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight_542775.html","title":{"rendered":"CAR T-Cell Therapy for Multiple Myeloma Market Analysis, Market Size, Trends, Epidemiology, Leading Companies And Competitive Analysis By Delveinsight"},"content":{"rendered":"
\"CAR<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u201cCAR T-Cell Therapy for Multiple Myeloma\u2013 Market Insights, Epidemiology, and Market Forecast-2030\u2033 report delivers an in-depth understanding of the CAR T-Cell Therapy for Multiple Myeloma, historical and forecasted epidemiology as well as the CAR T-Cell Therapy for Multiple Myeloma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

DelveInsight has launched a new report on “CAR T-Cell Therapy for Multiple Myeloma- Market Insights, Epidemiology, and Market Forecast-2030<\/a><\/strong><\/p>\n

DelveInsight’s<\/span> “CAR T-Cell Therapy for Multiple Myeloma– Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a>″<\/span> report delivers an in-depth understanding of the CAR T-Cell Therapy for Multiple Myeloma, historical and forecasted epidemiology as well as the CAR T-Cell Therapy for Multiple Myeloma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/span><\/p>\n

Some of the key facts of the Report:<\/strong><\/p>\n

    \n
  1. \n

    Market Size of CAR T-Cell Therapy for Multiple Myeloma in the 6MM is expected to be USD 3,766.4 Million in 2030<\/span><\/p>\n<\/li>\n

  2. \n

    According to WHO, in 2018, 159,985 incident cases of multiple myeloma were reported in the world. <\/span><\/p>\n<\/li>\n<\/ol>\n

    Key benefits of the report:<\/strong><\/p>\n

    1. CAR T-Cell Therapy for Multiple Myeloma market report covers a descriptive overview and comprehensive insight of the  CAR T-Cell Therapy for Multiple Myeloma epidemiology and CAR T-Cell Therapy for Multiple Myeloma market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/span><\/p>\n

    2. CAR T-Cell Therapy for Multiple Myeloma market report provides insights on the current and emerging therapies.<\/span><\/p>\n

    3. CAR T-Cell Therapy for Multiple Myeloma market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/span><\/p>\n

    4. The CAR T-Cell Therapy for Multiple Myeloma market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the CAR T-Cell Therapy for Multiple Myeloma market.<\/span><\/p>\n

    Request for sample pages: https:\/\/www.delveinsight.com\/sample-request\/car-t-cell-therapy-for-multiple-myeloma-market<\/a><\/strong><\/p>\n

    CAR T-Cell Therapy for Multiple Myeloma: Overview<\/strong><\/p>\n

    CAR T uses a patient’s own T cells which are removed and then engineered to identify and kill malignant multiple myeloma cells. The use of a patient’s own immune cells to fight cancer is proving to be a promising therapeutic approach in the treatment of lymphomas and is now advancing in multiple myeloma.<\/span><\/p>\n

    The key players involved in CAR T-Cell Therapy for Multiple Myeloma market:<\/strong><\/p>\n

      \n
    1. \n

      Celgene<\/span><\/p>\n<\/li>\n

    2. \n

      Janssen<\/span><\/p>\n<\/li>\n

    3. \n

      Poseida Therapeutics<\/span><\/p>\n<\/li>\n

    4. \n

      MolMed<\/span><\/p>\n<\/li>\n

    5. \n

      Juno Therapeutics <\/span><\/p>\n<\/li>\n

    6. \n

      Cartesian Therapeutics<\/span><\/p>\n<\/li>\n

    7. \n

      Precision BioSciences<\/span><\/p>\n<\/li>\n<\/ol>\n

      The launch of the emerging therapies is expected to significantly impact the CAR T-Cell Therapy for Multiple Myeloma treatment<\/a> scenario in the upcoming years:-<\/strong><\/p>\n

      Drug covered<\/strong><\/p>\n

        \n
      1. \n

        bb2121 <\/span><\/p>\n<\/li>\n

      2. \n

        JNJ-68284528<\/span><\/p>\n<\/li>\n

      3. \n

        P-BCMA-101<\/span><\/p>\n<\/li>\n

      4. \n

        CAR-CD44v6<\/span><\/p>\n<\/li>\n

      5. \n

        JCARH125<\/span><\/p>\n<\/li>\n

      6. \n

        Descartes-08<\/span><\/p>\n<\/li>\n

      7. \n

        PBCAR269A<\/span><\/p>\n<\/li>\n<\/ol>\n

        Request a free sample report @https:\/\/www.delveinsight.com\/sample-request\/car-t-cell-therapy-for-multiple-myeloma-market<\/a><\/strong><\/p>\n

        Table of Contents<\/strong><\/p>\n

        1. Report Introduction<\/span><\/p>\n

        2. Executive Summary<\/span><\/p>\n

        3. SWOT analysis<\/span><\/p>\n

        4. CAR T-Cell Therapy for Multiple Myeloma Patient Share (%) Overview at a Glance<\/span><\/p>\n

        5. CAR T-Cell Therapy for Multiple Myeloma Market Overview at a Glance<\/span><\/p>\n

        6. CAR T-Cell Therapy for Multiple Myeloma Disease Background and Overview<\/span><\/p>\n

        7. CAR T-Cell Therapy for Multiple Myeloma Epidemiology and Patient Population<\/span><\/p>\n

        8. Country-Specific Patient Population of  CAR T-Cell Therapy for Multiple Myeloma<\/span><\/p>\n

        9. CAR T-Cell Therapy for Multiple Myeloma Current Treatment and Medical Practices<\/span><\/p>\n

        10. Unmet Needs<\/span><\/p>\n

        11. CAR T-Cell Therapy for Multiple Myeloma Emerging Therapies<\/span><\/p>\n

        12. CAR T-Cell Therapy for Multiple Myeloma Market Outlook<\/span><\/p>\n

        13. Country-Wise  CAR T-Cell Therapy for Multiple Myeloma Market Analysis (2017–2030)<\/span><\/p>\n

        14. Market Access and Reimbursement of Therapies<\/span><\/p>\n

        15. Market drivers<\/span><\/p>\n

        16. Market barriers<\/span><\/p>\n

        17. Appendix<\/span><\/p>\n

        18. CAR T-Cell Therapy for Multiple Myeloma Report Methodology<\/span><\/p>\n

        19. DelveInsight Capabilities<\/span><\/p>\n

        20. Disclaimer<\/span><\/p>\n

        21. About DelveInsight<\/span><\/p>\n

        Related Reports:<\/strong><\/p>\n

        CAR T-Cell Therapy for Multiple Myeloma- Pipeline Insights, 2021<\/strong><\/p>\n

        “<\/span>CAR T-Cell Therapy for Multiple Myeloma Pipeline Insight, 2021<\/span>” report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the CAR T-Cell Therapy for Multiple Myeloma market. A detailed picture of the CAR T-Cell Therapy for Multiple Myeloma pipeline landscape is provided, which includes the disease overview and  CAR T-Cell Therapy for Multiple Myeloma treatment guidelines.<\/span><\/p>\n

        Media Contact<\/span>
        Company Name:<\/strong>         DelveInsight Business Research LLP<\/a>
        Contact Person:<\/strong> Kritika Rehani
        Email:<\/strong>         Send Email<\/a>
        Phone:<\/strong> 9193216187
        Address:<\/strong>304 S. Jones Blvd #2432
        City:<\/strong> Las Vegas
        State:<\/strong> Nevada
        Country:<\/strong> United States
        Website:<\/strong>         https:\/\/www.delveinsight.com\/<\/a><\/p>\n

        <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

        DelveInsight Business Research LLP DelveInsight\u2019s \u201cCAR T-Cell Therapy for Multiple Myeloma\u2013 Market Insights, Epidemiology, and Market Forecast-2030\u2033 report delivers an in-depth understanding of the CAR T-Cell Therapy for Multiple Myeloma, historical and forecasted epidemiology as well as the CAR T-Cell … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-542775","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/542775","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=542775"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/542775\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=542775"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=542775"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=542775"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}